CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
CNS Pharmaceuticals (NASDAQ:CNSP) is set to participate in a live moderated video webcast on May 3, 2023, at 12:00 PM ET, focusing on its pivotal study for Berubicin, a treatment for recurrent glioblastoma multiforme (GBM). The CEO, CMO, and VP of Clinical Operations will discuss the study's progress, which has now opened 44 out of 60 planned clinical trial sites across the U.S. and Europe, with over 100 patients enrolled. A pre-planned interim analysis is anticipated in Q3 2023. This event will provide investors with insights into the ongoing developments in CNS Pharmaceuticals' pipeline aimed at treating aggressive brain and CNS cancers. The live webcast and a subsequent replay will be accessible on the company's website.
- None.
- None.
Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET
HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET.
As part of the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President, Clinical Operations of CNS Pharmaceuticals will discuss the progress of its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. To date, the Company has opened 44 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland and recently announced that over 100 patients have been enrolled in the study. The Company expects to conduct a pre-planned interim analysis in the third quarter of 2023.
A live video webcast of the event will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals
View source version on accesswire.com:
https://www.accesswire.com/751486/CNS-Pharmaceuticals-to-Present-at-the-Virtual-Investor-Spotlight-Event--Rapidly-Advancing-GBM-Pivotal-Study
FAQ
What is CNS Pharmaceuticals presenting on May 3, 2023?
How many clinical trial sites has CNS Pharmaceuticals opened for Berubicin?
When is the interim analysis for the Berubicin study expected?
How many patients have been enrolled in the Berubicin study so far?
Where can I watch the CNS Pharmaceuticals webcast?
